What is CTAP?

FDA has created a special emergency program for possible coronavirus therapies, the Coronavirus Treatment Acceleration Program (CTAP). The program uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness. Please see our Frequently Asked Questions page for more information on the program.

FDA Voices Articles on CTAP On April 20, 2020, Commissioner Hahn, CBER Director Marks, and CDER Director Woodcock explain FDA’s strategic approach to COVID-19 therapeutic development via a blog post, "CTAP: The Path Forward." On July 14, 2020, Commissioner Hahn, Acting CDER Director Cavazzoni and CBER Director Marks explain how we built and manage CTAP operations via a blog post, “CTAP: Behind the Scenes.”

CTAP Dashboard

This dashboard provides a snapshot of development of potential COVID-19 therapeutics. Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, the following numbers may change frequently. FDA will update these numbers monthly. As of August 31, 2020, the snapshot is: